calendar
15 catalysts · 7 phase 2 initiation · 3 phase 1 2 initiation · 2 phase 1 initiation · 1 phase 2 3 completion · 1 phase 2 completion · 1 phase 3 completion
15 catalysts · 7 phase 2 initiation · 3 phase 1 2 initiation · 2 phase 1 initiation · 1 phase 2 3 completion · 1 phase 2 completion · 1 phase 3 completion
Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Therapy area: Oncology. Indication: Thyroid Cancer
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Oncology. Indication: Lung Cancer
Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma
Therapy area: Oncology. Indication: Colorectal Cancer
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Therapy area: Oncology. Indication: Ovarian Cancer
Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma